Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.15

€1.15

-1.870%
-0.022
-1.870%
-
 
19.09.24 / Frankfurt WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cerenis Therapeutics Holding S.A. Stock

A loss of -1.870% shows a downward development for Cerenis Therapeutics Holding S.A..
For the coming years our community has positive and negative things to say abot the Cerenis Therapeutics Holding S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years

Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cerenis Therapeutics Holding S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cerenis Therapeutics Holding S.A. -1.870% -5.882% -9.005% 5.109% -6.494% 23.340% 310.695%
Sensorion SA -3.620% -2.740% 31.481% 33.333% 113.000% -58.841% -
Genoway S.A. Inh. 0.850% -2.452% -7.969% 1.994% -18.821% -13.527% 149.477%
Hybrigenics S.A. -15.290% -17.241% 16.129% -85.910% -61.905% -95.583% -93.706%

News

ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis


ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural